Last Update 10 Apr 26

HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Trading

Analysts now view Hologic’s value as effectively unchanged, with a refreshed price framework still centered around $76.67 per share as they factor in the pending $79 per share cash acquisition and recent downgrades to Hold related to the transaction’s expected early February close.

Analyst Commentary

Recent research focuses heavily on the pending all cash acquisition at up to $79 per share and how that affects the risk and reward for current shareholders. The shift in ratings to Hold reflects a view that the stock price and the proposed takeout value are now closely aligned, which can limit upside while the deal is pending.

Bullish Takeaways

Bullish analysts highlight that the agreed cash acquisition price of up to $79 per share provides a clear valuation reference point that is above the refreshed framework around $76.67 per share.
The transaction value of up to $18.3b is seen as a sign that large, well capitalized buyers are willing to commit substantial capital to acquire the entire company.
The expected early February closing gives investors a defined timeline for when the proposed value realization could occur, which can reduce uncertainty around execution.
With an agreed deal in place, some bullish analysts see less need to underwrite long term execution or growth assumptions, since the primary focus shifts to deal completion rather than multi year performance.

Bearish Takeaways

Bearish analysts shifting ratings to Hold point to a more limited upside from current trading levels to the proposed $79 per share cash consideration, which can reduce the appeal for new buyers focused on return potential.
Once a company is under an agreed acquisition, trading can become more tied to perceived deal risk and timing than to ongoing operating execution or growth, which may not suit investors seeking exposure to fundamental business drivers.
If the share price already reflects most of the proposed transaction value, bearish analysts see less margin of safety for investors should there be any delays or changes to the deal terms.
The move from Buy to Hold signals that, in the eyes of these analysts, the risk and reward have become more balanced rather than skewed toward material upside on standalone execution.

What’s in the News

Funds managed by Blackstone and TPG, alongside minority investors ADIA and GIC, completed the acquisition of Hologic for up to $79 per share. Hologic became a private company and its common stock ceased to trade on the Nasdaq Stock Market (M&A Transaction Closings, Legal Structure Changes, Delistings).
Following the go-private deal, Hologic has been or will be removed from multiple major equity indices, including the S&P 500, S&P Global BMI, S&P Global 1200, FTSE All World, Russell 1000, Russell 3000 and related value, defensive, midcap and sector indices, as well as the Nasdaq Composite Index (Index Constituent Drops).
José (Joe) E. Almeida was appointed Chief Executive Officer, succeeding retiring CEO Stephen MacMillan. Almeida brings prior leadership experience from Baxter International and Covidien (Executive Changes, CEO).
Hologic’s Aptima HPV Assay received FDA approval for clinician-collected HPV primary screening, expanding the company’s cervical cancer screening offerings across Pap testing, HPV primary testing and co-testing (Product Related Announcements).
The FDA reported a voluntary Class II recall of certain Aptima HPV Assay kits, citing potential for invalid or false negative results. The products were distributed across several U.S. states and the recall status is listed as ongoing (Product Related Announcements).

Valuation Changes

Fair Value: stays at $76.67 per share, with no change from the prior estimate.
Discount Rate: has risen slightly from 8.02% to 8.09%, implying a modestly higher required return for the equity.
Revenue Growth: remains effectively unchanged at about 4.86% in the updated framework.
Net Profit Margin: is essentially flat at roughly 20.13%, with no material revision to expected profitability.
Future P/E: edges up slightly from 22.60x to 22.64x, reflecting a minor adjustment to the valuation multiple applied to future earnings.

2 views

Key Takeaways

Innovation in core diagnostic and screening technologies, supported by AI integration, is driving market share gains and expanding margins through premium offerings and product upgrades.
Portfolio expansion, strategic acquisitions, and improved operations are diversifying revenue, supporting resilience, and fueling sustained growth across international markets.
Structural and persistent international, segment, and margin challenges threaten revenue growth, profitability, and earnings momentum without successful execution of higher-margin innovation and market recovery.

Catalysts

About Hologic

Engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide.What are the underlying business or industry changes driving this perspective?

The global rise in preventive women's health and the aging population, combined with growing healthcare expenditure (especially in emerging markets), are positioning Hologic's core businesses for long-term growth. This underlies sustained demand for diagnostic and screening products and should drive higher utilization and recurring revenue.
Continued innovation in 3D mammography and the planned launch of the next-generation Envision system, alongside the integration of AI-driven Genius Detection PRO, position Hologic to capture greater market share, enable premium pricing, and drive margin expansion as older gantries are replaced and product upgrades accelerate.
Expansion of the molecular diagnostics portfolio (notably Panther Fusion assay menu and increased U.S. adoption of new tests for women's health) is broadening the recurring revenue base and supporting steady organic growth, with runway provided by both increased test menu and untested patient populations.
Strategic M&A (notably Endomag and Gynesonics) and accelerated international expansion in surgical and interventional breast health products are increasing revenue diversification and scale, enhancing resilience against U.S. market fluctuations and supporting top-line growth and operating margin improvement.
Operational improvements-including optimized salesforce execution, targeted end-of-life upgrades, and substantial mitigation of supply chain tariff impacts-are restoring growth momentum and efficiency, supporting EPS recovery and stabilizing or improving net margins into fiscal 2026 and beyond.

Hologic Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Hologic's revenue will grow by 4.9% annually over the next 3 years.
Analysts assume that profit margins will increase from 13.2% today to 20.1% in 3 years time.
Analysts expect earnings to reach $957.9 million (and earnings per share of $4.34) by about April 2029, up from $543.8 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $1.1 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 22.7x on those 2029 earnings, down from 31.2x today. This future PE is lower than the current PE for the US Medical Equipment industry at 26.3x.
Analysts expect the number of shares outstanding to grow by 0.18% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.09%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The company is experiencing significant, ongoing headwinds in China due to a challenging operating environment and substantial revenue declines (down over 50% YoY and now less than $10M/quarter versus $60-70M annualized); this creates a risk of sustained weakness in international revenue growth and dampens overall corporate revenue and earnings momentum into fiscal 2026.
Funding cuts to U.S. aid in Africa, notably impacting the HIV diagnostics business, have reduced demand and are expected to persist, representing another structural headwind to international diagnostics revenue and compressing consolidated revenue growth in the first half of fiscal 2026.
Tariffs remain a substantial headwind despite recent mitigation efforts; Hologic expects $10-12M per quarter in ongoing tariff expenses, translating to nearly 100 basis points of gross margin pressure in fiscal 2026, directly impacting net margins and profitability.
The Breast Health segment remains exposed to elongated gantry replacement cycles and declining legacy system revenues, heightening the risks associated with over-dependence on this business line and leaving revenue and earnings vulnerable to slower-than-expected product upgrades or replacement demand.
Gross and operating margin trends are under structural pressure due to product mix shifts (including lower-margin and discontinued products like Fluoroscan), dilutive effects from recent acquisitions, and residual COVID testing declines, putting sustained net margin expansion and long-term earnings growth at risk unless higher-margin innovation and volume growth materialize as planned.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $76.67 for Hologic based on their expectations of its future earnings growth, profit margins and other risk factors.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $4.8 billion, earnings will come to $957.9 million, and it would be trading on a PE ratio of 22.7x, assuming you use a discount rate of 8.1%.
Given the current share price of $76.01, the analyst price target of $76.67 is 0.9% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Hologic?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

HOLX: Downgrades And Buyout Agreement Will Shift Near-Term Share Performance